The PCOS pipeline: tiny but diverse

Women with polycystic ovary syndrome have no FDA-approved treatment options. That situation is unlikely to change in the near term, but a small set of disclosed programs suggests the indication is on the radar of at least a few companies.

Polycystic ovary syndrome (PCOS) is a major cause of infertility, with hormone imbalances that can be masculinizing. It can also predispose women to obesity and insulin resistance. As with other women’s health indications, the condition has been largely ignored by drug developers. ...